Stablepharma
PrivateLast Round
Grant
Feb 19, 2025
Est. Valuation
$50.25M
Total Funding Raised
$12.31M
Company Overview
Stablepharma is a biotechnology company that develops a technology platform to transform approved vaccines, therapeutics, and diagnostics into thermostable products, ensuring safe and efficient delivery while minimizing waste and carbon emissions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Stablepharma Comparables
Compare Stablepharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VitriVax, Inc. | 87% | |
| Elarex Inc. | 84% | |
| Inaedis Inc. | 84% |
Stablepharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 19, 2025 | ||||
| Crowdfunding | Jun 14, 2024 | ||||
| VC Round | Oct 23, 2023 | ||||
| Grant | Sep 12, 2023 | ||||
| Series A | Dec 23, 2022 | ||||
Crowdfunding | Aug 5, 2021 |
Key People
Founding team and executive leadership
Stablepharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Crowdcube Investors | Crowdfunding, VC Round, Series A, Seed |
| European Innovation Council Fund | Grant |
| Ascension Ventures | Series A |
| Innovate UK | Grant |
| Oval Investments Limited | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 13, 2026
SPVX02 targets tetanus and diphtheria, developed with UKHSA support.
- Jan 15, 2026
Developing fridge-free sterile injectable medicines with AFT Pharmaceuticals.
Recent news
Latest coverage and updates
- is_developingSep 18, 2026
Stablepharma is developing SPVX02 on Sep 18th '26.
- is_developingAug 9, 2026
Stablepharma will develop SPVX02 on Jul 1st '27.
- is_developingJul 27, 2026
Stablepharma is developing temperature-stabilised injectable drugs.
- receives_awardJul 8, 2026
Stablepharma Ltd receives award Solidarity Award at 2026 Ciudad de Tres Cantos Business Awards Gala.
- attends_eventJul 8, 2026
Stablepharma Ltd attends event 2026 Ciudad de Tres Cantos Business Awards Gala.
Stablepharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Stablepharma's valuation, stock price, and market status.
Is Stablepharma a public or private company?
Stablepharma is a private company.
What is the current stock price of Stablepharma?
Stablepharma is a private company with no public stock price. No recent secondary market data is available.
How much is Stablepharma worth (valuation)?
Stablepharma's valuation is estimated at $50.3M based on funding round data.
Can I buy Stablepharma stock?
Stablepharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Stablepharma's last funding round?
Stablepharma's most recent funding round was Grant on December 23, 2022.
Who are the main investors in Stablepharma?
Key investors in Stablepharma include European Innovation Council.
Will Stablepharma IPO soon?
No public IPO plans have been announced for Stablepharma.
How can I track Stablepharma secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Stablepharma's secondary market activity and sign up for updates.